Literature DB >> 6265140

Metabolism of antithrombin III in cirrhosis and carcinoma of the liver.

V Chan, C L Lai, T K Chan.   

Abstract

1. The metabolism of human antithrombin III (ATIII) was studied by using 125I-labelled tracer. 2. The plasma half-life (t0.5) was 2.71 +/- 0.26 days in normal subjects and was similar in patients with cirrhosis or primary carcinoma of liver. 3. Patients with cirrhosis had low ATIII levels, decreased intravascular mass, total body mass and decreased absolute catabolic rate, suggesting decreased synthesis. The positive correlation of ATIII level with fractional catabolic rate (K10) indicated that the decreased catabolic might exert a positive inhibition on ATIII production. 4. These abnormalities were more exaggerated in patients with macronodular cirrhosis associated with hepatitis surface antigen or in those with ascites. 5. In cirrhotic patients with ascites an additional extravascular pool of ATIII was present which did not turn over at the same rate as the intravascular pool. 6. Patients with primary carcinoma of liver had moderately low ATIII, but normal intravascular mass and total body mass because of the increased plasma volume and normal absolute catabolic rate. 7. The negative correlation of ATIII levels with K10 suggested that the low levels could be due to increased catabolism or consumption. 8. One patient with disseminated malignancy and active superficial thrombophlebitis had normal ATIII metabolism.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6265140     DOI: 10.1042/cs0600681

Source DB:  PubMed          Journal:  Clin Sci (Lond)        ISSN: 0143-5221            Impact factor:   6.124


  3 in total

1.  Proteases and antiproteases related to the coagulation system in plasma and ascites--an approach to differentiate between malignant and cirrhotic ascites.

Authors:  J Schölmerich; U Zimmermann; E Köttgen; B A Volk; S Ehlers; W Gerok
Journal:  Klin Wochenschr       Date:  1987-07-15

2.  In vivo behavior of radioiodinated rabbit antithrombin III. Demonstration of a noncirculating vascular compartment.

Authors:  T H Carlson; A C Atencio; T L Simon
Journal:  J Clin Invest       Date:  1984-07       Impact factor: 14.808

3.  Antithrombin III metabolism in patients with liver disease.

Authors:  E Knot; J W Ten Cate; H R Drijfhout; L H Kahlé; G N Tytgat
Journal:  J Clin Pathol       Date:  1984-05       Impact factor: 3.411

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.